Bavarian Nordic

Today, we published our first half results for 2024. Commenting on the results, Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We are pleased to report strong developments for Bavarian Nordic during the first half of 2024. Unfortunately, mpox is again making global headlines as a result of the record number of cases reported in Africa. The situation has urged the African CDC and the WHO to declare public health emergencies and Bavarian Nordic is working closely with all stakeholders to ensure the equitable access to our mpox vaccine. Importantly, we have built a strong partnership with the Africa Centers of Disease Control (CDC), both on exploring supply, but also expanding our manufacturing network to include Africa. We are also working with the WHO on a regulatory path to ensure access to all countries, while in parallel seeking approval for use in adolescents and also conducting clinical studies in Africa to further expand the use to children. A recent order for MVA-BN was secured by an undisclosed European country, and this was anticipated as part of the 2024 guidance and as such, has no impact on the remaining vaccine capacity. Indeed, in response to recent events the company plans to ramp-up vaccine manufacturing to ensure the continued equitable access to our mpox vaccine. Consequently, we have the capacity to manufacture 10 million doses by the end of 2025, in addition to our current orders, and could already supply up to 2 million doses this year. Bavarian Nordic is prepared to work with the international community to play our role in protecting and saving lives around the World and to contain the latest outbreak.” Read more in the full report: https://lnkd.in/dAWqhQ6U

Are you an inclusive colleague? After our first insightful webinar with Sara Louise Muhr in June, where we delved into the topic of bias, we recently had the privilege of hosting our second webinar with her. This time on the topic of inclusive colleagueship. Inclusive workplaces are about sparking ongoing conversations and taking tangible steps to foster an inclusive environment. This can be done by: 🌟 Ask flip questions to change your perceptions in that moment 🌟 Change the order in which people speak 🌟 Check in on your quieter team members (or colleagues) before a meeting 🌟 Get a bias-buddy  As we continue to learn and grow, we must all take an active role in building and nurturing inclusivity in our workspace. #BavarianNordic #DEI

August 20 is #WorldMosquitoDay and we are shedding light on Chikungunya, a lesser-known mosquito-borne disease prevalent in popular travel destinations across South-East Asia, Latin America, and Africa.   Recently, the World Health Organization has highlighted that climate change is accelerating the spread of mosquito-borne viruses, creating favorable conditions for mosquitoes even in previously unaffected regions like Europe and the USA. This increases the risk of local Chikungunya transmission. Stay protected from mosquito bites: ✔ Use insect repellents ✔ Wear long clothes ✔ Use mosquito screens #Chikungunya #Mosquitos  #ProtectingLivesEveryDay

Statement from Bavarian Nordic on mpox vaccine supply and collaboration with African and global stakeholders: Bavarian Nordic today provided an update on its plans for securing supply of vaccines to tackle the current #mpox outbreak that the Africa Centers for Disease Control and Prevention (Africa CDC) declared as a Public Health Emergency of Continental Security (PHECS) on August 13, 2024, followed by the World Health Organization (WHO) that declared mpox as a Public Health Emergency of International Concern (PHEIC) on August 14, 2024.   “Bavarian Nordic is working closely with all stakeholders to ensure equitable access to our mpox vaccine during the current PHECS and PHEIC. Importantly, we have built a strong partnership with the Africa CDC, both on supply, but also expanding our manufacturing network to include Africa. We are also working with the WHO on a regulatory path to ensure access to all countries, while in parallel seeking approval for use in adolescents and conducting clinical studies in Africa to further expand the use to children. We are prepared to work with the Africa CDC and the international community to play our role in protecting and saving lives around the World and to contain the latest outbreak,” said Paul Chaplin, President & CEO of Bavarian Nordic. Read the full statement: https://lnkd.in/d37emiNP

Partnering to strengthen global support in the fight against #mpox in Africa   Today, we entered a procurement agreement with the European Commission's Health Emergency Preparedness and Response Authority (HERA) for our mpox vaccine as part of a joint contribution to the Africa CDC, who today declared mpox a Public Health Emergency of Continental Security.   HERA has procured over 175,000 doses and Bavarian Nordic will donate 40,000 doses, totaling more than 215,000 doses to strengthen the mpox response in Africa.   “Mpox is spreading at an alarming rate in Africa, calling for further action from the international community. We are proud to support HERA’s vaccine contribution to the region and are pleased to announce an additional donation from Bavarian Nordic. We also applaud the initiative from the Africa CDC to strengthen and coordinate the public health response, helping to ensure our vaccine can reach more people on the African continent,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic.   Read more: https://lnkd.in/dQbWYw96

Today, the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review for the Biologics License Application (BLA) for our CHIKV VLP vaccine for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older.    “We are encouraged by the FDA’s decision to grant Priority Review to our chikungunya vaccine, allowing for a shorter review time, and we look forward to working closely with the regulators to make our vaccine available to individuals 12 years of age and older at risk of chikungunya virus infection,” said Paul Chaplin, President and CEO of Bavarian Nordic. Read more: https://lnkd.in/dJC4gYnE

Hi, I am Glenn Omanio, and I am the US Marketing Director at Bavarian Nordic.     As the leader of our US Marketing team, I oversee pre-launch and launch activities and provide our sales team with the essential resources to bring our vaccines to those who need them. What truly makes me proud to work here at Bavarian Nordic is that I can connect what I personally believe in with something much bigger – the greater good. I find the culture here at Bavarian Nordic to be inspired by togetherness. In our team, we face challenges head-on and together. For us, it’s really all about being ‘boosted by the team’ and supporting each other where needed. If you want to join me in Bavarian Nordic, check out our open positions: https://lnkd.in/eG9TCbF #BavarianNordicDNA #pharma #Vaccine #Portectingliveseveryday #Boostedbytheteam

Today, we announced the award of a new order from the U.S. government for our mpox/smallpox vaccine. The order, valued at USD 156.8 million, will help replenish the bulk vaccine inventory used to manufacture vaccines in response to the mpox outbreak in 2022. The additional production of bulk vaccine will enable us to fulfill our existing contract to supply a next-generation, freeze-dried version of the vaccine for U.S. smallpox preparedness. Paul Chaplin, President and CEO of Bavarian Nordic commented: "We applaud the U.S. government’s steadfast commitment to maintaining a robust preparedness and are proud to continue providing vaccines to protect its citizens against current and future public health threats.” Read more: https://lnkd.in/dQDRdXij

As a leading pure-play vaccine company, we acknowledge our responsibility to ensure sustainable operations. Our primary impact on the environment is derived from our vaccine manufacturing, which means that when we expand our access to vaccines, we also increase our environmental impact. We take on the responsibility of reducing this impact. To reach this goal, we have defined our pathway to Net Zero and are tracking our environmental footprint, with the purpose of saving lives and protecting the environment at the same time. Read more in our Sustainability Report: https://lnkd.in/d54zGxDz

Hi, I am Kurt Reichen, and I am the head of the Bern site at Bavarian Nordic.     As a Site Head, I ensure cross-department collaboration and enable performance to drive the vision of Bavarian Nordics' future. It makes me proud to see that our employees give their best every day and enjoy coming to work.   I find the culture here at Bavarian Nordic collaborative. For me, collaboration is when people work together to achieve goals. When working in our teams, there is always an open and trusting environment that invites people to speak their minds. Being able to protect lives every day makes a difference for me and drives my commitment. If you want to join me in Bavarian Nordic, check out our open positions: https://lnkd.in/eG9TCbF #BavarianNordicDNA #pharma #Collaboration #ProtectingLivesEveryDay